154 related articles for article (PubMed ID: 38772686)
21. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
Godwin CD; Laszlo GS; Fiorenza S; Garling EE; Phi TD; Bates OM; Correnti CE; Hoffstrom BG; Lunn MC; Humbert O; Kiem HP; Turtle CJ; Walter RB
Leukemia; 2021 Sep; 35(9):2496-2507. PubMed ID: 33589747
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
23. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
24. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
Caulier B; Joaquina S; Gelebart P; Dowling TH; Kaveh F; Thomas M; Tandaric L; Wernhoff P; Katyayini NU; Wogsland C; Gjerstad ME; Fløisand Y; Kvalheim G; Marr C; Kobold S; Enserink JM; Gjertsen BT; McCormack E; Inderberg EM; Wälchli S
Cell Rep Med; 2024 Jun; 5(6):101572. PubMed ID: 38754420
[TBL] [Abstract][Full Text] [Related]
25. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
Tashiro H; Sauer T; Shum T; Parikh K; Mamonkin M; Omer B; Rouce RH; Lulla P; Rooney CM; Gottschalk S; Brenner MK
Mol Ther; 2017 Sep; 25(9):2202-2213. PubMed ID: 28676343
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
28. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
30. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
31. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
Zheng W; O'Hear CE; Alli R; Basham JH; Abdelsamed HA; Palmer LE; Jones LL; Youngblood B; Geiger TL
Leukemia; 2018 May; 32(5):1157-1167. PubMed ID: 29479065
[TBL] [Abstract][Full Text] [Related]
32. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
[TBL] [Abstract][Full Text] [Related]
33. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
34. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Albinger N; Pfeifer R; Nitsche M; Mertlitz S; Campe J; Stein K; Kreyenberg H; Schubert R; Quadflieg M; Schneider D; Kühn MWM; Penack O; Zhang C; Möker N; Ullrich E
Blood Cancer J; 2022 Apr; 12(4):61. PubMed ID: 35418180
[TBL] [Abstract][Full Text] [Related]
35. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
36. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
37. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
38. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
39. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
El Khawanky N; Hughes A; Yu W; Myburgh R; Matschulla T; Taromi S; Aumann K; Clarson J; Vinnakota JM; Shoumariyeh K; Miething C; Lopez AF; Brown MP; Duyster J; Hein L; Manz MG; Hughes TP; White DL; Yong ASM; Zeiser R
Nat Commun; 2021 Nov; 12(1):6436. PubMed ID: 34750374
[TBL] [Abstract][Full Text] [Related]
40. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
